United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori  has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu

United States - English - NLM (National Library of Medicine)

allergan, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - pylera in combination with omeprazole are indicated for the treatment of patients with  helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori   has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to res

United States - English - NLM (National Library of Medicine)

h2-pharma, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

Canada - English - Health Canada

laboratoires juvise pharmaceuticals - bismuth oxide (bismuth subcitrate potassium); tetracycline hydrochloride; metronidazole - capsule - 40mg; 125mg; 125mg - bismuth oxide (bismuth subcitrate potassium) 40mg; tetracycline hydrochloride 125mg; metronidazole 125mg - tetracyclines

Israel - English - Ministry of Health

perrigo israel agencies ltd, israel - bismuth subsalicylate - chewable tablets - bismuth subsalicylate 262 mg - bismuth subcitrate - bismuth subcitrate - for relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.

Israel - English - Ministry of Health

perrigo israel agencies ltd, israel - bismuth sub salicylate - suspension - bismuth sub salicylate 262.50 mg / 15 ml - bismuth subcitrate - bismuth subcitrate - for relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.

United States - English - NLM (National Library of Medicine)

ailex pharmaceuticals, llc - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz) - the components of bismuth subsalicylate chewable tablets/ metronidazole tablets/tetracycline hydrochloride capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an h2 antagonist, are indicated for the eradication of h. pylori for treatment of patients with h. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). the eradication of h. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see clinical studies and dosage and administration ). to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subsalicylate chewable tablets/metronidazole tablets/tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptib

Malta - English - Medicines Authority

macarthys laboratories limited bampton road, harold hill, romford essex, rm3 8ug, united kingdom - bismuth subnitrate, iodoform, liquid paraffin - impregnated dressing - bismuth subnitrate 20 % (w/w) iodoform 40 % (w/w) liquid paraffin 40 % (w/w) - medicated dressings